Abstract
Phosphoinositide 3-kinases (PI3Ks) play an essential role in the intracellular signal transduction cascades initiated by the activation of cell surface receptors through their specific extracellular signals. PI3Ks control a variety of cellular responses, including growth, protection from apoptosis, motility, metabolism and intracellular protein sorting. Eight catalytic PI3K isoforms exist in human, which are grouped into three classes (I-III), based on structural homology and in vitro substrate specificity. Class I PI3Ks mediate signalling by receptor tyrosine kinases (RTKs) and G-proteincoupled receptors (GPCRs). The class II of PI3Ks, which comprises three distinct isoforms (PI3KC2α, PI3KC2β and PI3KC2γ) are less well characterized in terms of cellular functions. PI3KC2α and PI3KC2β are activated downstream of RTKs and GPCRs and play a role in cell migration, survival, glucose transport and endocytosis. Recently, the first isoform-specific small molecule inhibitors of PI3KC2β were described and evaluated as anti-proliferative agents in cancer. In this review, we will discuss the different regulatory mechanisms and functions of class II PI3Ks in the context of cell surface receptor signalling and their potential as novel drug targets in the field of oncology.
Keywords: Cancer, cell migration, G-protein-coupled receptor, phosphoinositide 3-kinase, receptor tyrosine kinase.
Current Signal Transduction Therapy
Title:Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Volume: 8 Issue: 2
Author(s): Alexandre Arcaro, Anna Borgstrom and Karolina Blajecka
Affiliation:
Keywords: Cancer, cell migration, G-protein-coupled receptor, phosphoinositide 3-kinase, receptor tyrosine kinase.
Abstract: Phosphoinositide 3-kinases (PI3Ks) play an essential role in the intracellular signal transduction cascades initiated by the activation of cell surface receptors through their specific extracellular signals. PI3Ks control a variety of cellular responses, including growth, protection from apoptosis, motility, metabolism and intracellular protein sorting. Eight catalytic PI3K isoforms exist in human, which are grouped into three classes (I-III), based on structural homology and in vitro substrate specificity. Class I PI3Ks mediate signalling by receptor tyrosine kinases (RTKs) and G-proteincoupled receptors (GPCRs). The class II of PI3Ks, which comprises three distinct isoforms (PI3KC2α, PI3KC2β and PI3KC2γ) are less well characterized in terms of cellular functions. PI3KC2α and PI3KC2β are activated downstream of RTKs and GPCRs and play a role in cell migration, survival, glucose transport and endocytosis. Recently, the first isoform-specific small molecule inhibitors of PI3KC2β were described and evaluated as anti-proliferative agents in cancer. In this review, we will discuss the different regulatory mechanisms and functions of class II PI3Ks in the context of cell surface receptor signalling and their potential as novel drug targets in the field of oncology.
Export Options
About this article
Cite this article as:
Arcaro Alexandre, Borgstrom Anna and Blajecka Karolina, Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets, Current Signal Transduction Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15743624113086660002
DOI https://dx.doi.org/10.2174/15743624113086660002 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Docking Studies of Glutamine Valproic Acid Derivative (S)-5- amino-2-(heptan-4-ylamino)-5-oxopentanoic Acid (Gln-VPA) on HDAC8 with Biological Evaluation in HeLa Cells
Anti-Cancer Agents in Medicinal Chemistry Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry 2,3-Dichloro-1,4-Naphthoquinone in Organic Synthesis: Recent Advances
Mini-Reviews in Organic Chemistry Preparation and Biodistribution of Technetium-99m-Labeled Bis- Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia
Medicinal Chemistry Diabetic Gastroenteropathy: Soothe the Symptoms or Unravel a Cure?
Current Diabetes Reviews Imaging Virus-Associated Cancer
Current Pharmaceutical Design Mucosal Vaccine Vectors: Replication-Competent Versus Replication-Deficient Poxviruses
Current Pharmaceutical Design Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Current Signal Transduction Therapy Cultured Adult Animal Neurons and Schwann Cells Give Us New Insights into Diabetic Neuropathy
Current Diabetes Reviews Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery
Current Pharmaceutical Design Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)
Current Cancer Drug Targets The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry